Sanofi and SK Chemicals Sign Licensing Agreement for Flu Vaccine Technology
12 Febbraio 2018 - 6:36PM
Dow Jones News
By Sonia Amaral Rohter
Sanofi SA's (SAN.FR) vaccines division, Sanofi Pasteur, and SK
Chemicals Co. Ltd. (285130.SE) have signed a licensing agreement
for flu vaccine technology, SK Chemicals said on Monday.
Under the terms of the agreement, Sanofi Pasteur will pay SK
Chemicals up to $155 million, including milestone payments, to
license SK Chemicals's cell-culture based manufacturing technology
for influenza vaccines.
Sanofi Pasteur is licensing the technology for use in its
efforts to develop a broadly protective flu vaccine, SK Chemicals
said. Broadly protective influenza vaccines are designed to protect
against many different strains of the virus.
"We're pleased to license this innovative technology today, as
it brings us a step forward in the development of a future
broadly-protective influenza vaccine, a key priority for Sanofi
Pasteur," said Sanofi Pasteur Chief Executive David Loew.
Sanofi Pasteur is the world's largest producer of influenza
vaccine, according to its webpage.
Write to Sonia Amaral Rohter at
sonia.amaralrohter@dowjones.com
(END) Dow Jones Newswires
February 12, 2018 12:21 ET (17:21 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Grafico Azioni Sanofi (EU:SAN)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Sanofi (EU:SAN)
Storico
Da Apr 2023 a Apr 2024